Skip to content

Lupin shares gain on tentative USFDA approval for Valbenazine capsules

Lupin also announced that USFDA has completed a post-marketing adverse drug experience (PADE) inspection of the company’s operations, which closed with no observations.

Read More

​ Lupin also announced that USFDA has completed a post-marketing adverse drug experience (PADE) inspection of the company’s operations, which closed with no observations. Lupin also announced that USFDA has completed a post-marketing adverse drug experience (PADE) inspection of the company’s operations, which closed with no observations.  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish